Myeloproliferative Disorders Trial Results
Azacitidine Improves Survival in Myelodysplastic Syndromes
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.
Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.
Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.